Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity. (2023). SKIN The Journal of Cutaneous Medicine, 7(6), s274. https://doi.org/10.25251/skin.7.supp.274